Pelthos Therapeutics Inc. PTHS
7.44 USD -0.59 (-7.35%)
Regular-session close
7.44 0.00 0.00%
After hours · Nov 13, 4:00 PM ET
7.27 Day range 8.46
7.27 52-week range 34.68
- YTD
- -76.00%
- 1 year
- -78.55%
- Market cap
- 29.24M
- EPS (ttm)
- -23.86
- YTD return
- -76.00%
- 1-year return
- -78.55%
- Volume
- 53.96K
- Avg volume
- 50.77K
- Open
- 7.87
- Previous close
- 8.03
- Day's range
- 7.27 – 8.46
- 52-week range
- 7.27 – 34.68
5D -2.41 (-23.08%)
Fundamental scorecard
3 of 25 checks passed on PTHS’s reported financials
3of 25 checks passed
- Value 0 of 5
- Growth 2 of 5
- Profitability 0 of 5
- Financial health 1 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
PTHS Revenue — quarterly 15.39M
PTHS Net income — quarterly -7.89M
PTHS EPS — quarterly -2.04
News
Piper Sandler Reiterates Overweight on Pelthos Therapeutics, Lowers Price Target to $21
Oppenheimer Maintains Outperform on Pelthos Therapeutics, Lowers Price Target to $59
Pelthos Therapeutics Inc. (PTHS) Q3 2026 Earnings Call Transcript
Pelthos Therapeutics Q3 2026 Earnings Call Transcript
Pelthos Therapeutics Inc. (PTHS) Reports Q3 Loss, Lags Revenue Estimates Pelthos Therapeutics Q3 EPS $(2.04) Beats $(3.07) Estimate, Sales $15.395M Miss $17.605M Estimate
Pelthos Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Update
12 Health Care Stocks Moving In Friday's Intraday Session Pelthos Therapeutics Strikes Business Combination Agreement With Castle Creek Biosciences; Shareholders Of Castle Creek Biosciences To Receive 5.2M Common Shares Of Pelthos
Lake Street Maintains Buy on Pelthos Therapeutics, Lowers Price Target to $40
Your note
Sign in to keep a note on PTHS — it syncs with the Stock Master app.
